Literature DB >> 7277205

Predicting individual phenytoin dosage.

S Vozeh, K T Muir, L B Sheiner, F Follath.   

Abstract

Most previously suggested methods for predicting phenytoin dosage from steady-state drug levels (Cpss) measured in the clinical setting fail to fully exploit all relevant (population) information. A bayesian prediction method, applicable to any drug, is available. It appropriately combines all types of information. In this paper, we compare the Bayesian method as applied to phenytoin to two other prediction methods (and a baseline, nonfeedback one). Actual doses are compared to predictions in 49 patients. Each method is optimized, as far as possible, for the test data. The comparison favors the Bayesian method. Since each of the other prediction methods for phenytoin can be shown to be a theoretically suboptimal special case of the Bayesian one, the superiority of the latter may be a general phenomenon. Because the pharmacokinetic model linking steady-state phenytoin levels and dosage is so simple, a good approximation of the general Bayesian method can be implemented as a graphical device, or as a program for a programmable calculator. We present and describe both of these approximations.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7277205     DOI: 10.1007/BF01068078

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  17 in total

1.  A study of the pharmacokinetics of phenytoin (diphenylhydantoin) in epileptic patients, and the development of a nomogram for making dose increments.

Authors:  A Richens
Journal:  Epilepsia       Date:  1975-11       Impact factor: 5.864

2.  Forecasting individual pharmacokinetics.

Authors:  L B Sheiner; S Beal; B Rosenberg; V V Marathe
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

Review 3.  Pharmacodynamic and pharmacokinetic measurements of antiepileptic drugs.

Authors:  H Kutt
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

4.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors:  M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal:  N Engl J Med       Date:  1971-07-29       Impact factor: 91.245

5.  Metabolic disposition of diphenylhydantoin in normal human subjects following intravenous administration.

Authors:  A J Glazko; T Chang; J Baukema; W A Dill; J R Goulet; R A Buchanan
Journal:  Clin Pharmacol Ther       Date:  1969 Jul-Aug       Impact factor: 6.875

6.  Predicting phenytoin dose - a revised nomogram.

Authors:  B Rambeck; H E Boenigk; A Dunlop; P W Mullen; J Wadsworth; A Richens
Journal:  Ther Drug Monit       Date:  1979       Impact factor: 3.681

7.  Serum-phenytoin levels in management of epilepsy.

Authors:  A Richens; A Dunlop
Journal:  Lancet       Date:  1975-08-09       Impact factor: 79.321

8.  Letter: Phenytoin dosage nomogram.

Authors:  L Lund; G Alvan
Journal:  Lancet       Date:  1975-12-27       Impact factor: 79.321

9.  The clinical pharmacokinetics of phenytoin.

Authors:  E Martin; T N Tozer; L B Sheiner; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

10.  Predictability of phenytoin serum levels by nomograms and clinicians.

Authors:  S Vozeh; A Koelz; E Martin; H Magun; G Scollo-Lavizzari; F Follath
Journal:  Eur Neurol       Date:  1980       Impact factor: 1.710

View more
  35 in total

Review 1.  Therapeutic drug monitoring of phenytoin. Rationale and current status.

Authors:  M Levine; T Chang
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

3.  Classical Michaelis-Menten and system theory approach to modeling metabolite formation kinetics.

Authors:  Jovan Popović
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Jul-Sep       Impact factor: 2.441

Review 4.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

5.  Evaluation of a bayesian pharmacokinetic program for phenytoin concentration predictions in outpatient population.

Authors:  J M Gaulier; R Boulieu; C Fischer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

Review 6.  Clinical pharmacokinetics 1990.

Authors:  G R Matzke; W L St Peter
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

7.  Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine.

Authors:  A Mallet; F Mentré; J L Steimer; F Lokiec
Journal:  J Pharmacokinet Biopharm       Date:  1988-06

8.  Rapid prediction of individual dosage requirements for lignocaine.

Authors:  S Vozeh; M Berger; M Wenk; R Ritz; F Follath
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

9.  Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.

Authors:  D Fabre; F Bressolle; R Goméni; O Bouvet; A Dubois; C Raffanel; J C Gris; M Galtier
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 10.  Population pharmacokinetics. Theory and clinical application.

Authors:  B Whiting; A W Kelman; J Grevel
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.